{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:54:56Z","timestamp":1794635696125,"version":"4.9.1"},"reference-count":52,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Our investigation uncovers that nanomolar concentrations of salinomycin, monensin, nigericin, and narasin (a group of potassium\/ sodium cation carriers) robustly enhance surface expression of CD20 antigen in B-cell-derived tumor cells, including primary malignant cells of chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Experiments in vitro, ex vivo, and animal model reveal a novel approach of combining salinomycin or monensin with therapeutic anti-CD20 monoclonal antibodies or anti-CD20 chimeric antigen receptor T cells, significantly improving non-Hodgkin lymphoma therapy. The results of RNA sequencing, genetic editing, and chemical inhibition delineate the molecular mechanism of CD20 upregulation, at least partially, to the downregulation of MYC, the transcriptional repressor of the MS4A1 gene encoding CD20. Our findings propose the cation carriers as compounds targeting MYC oncogene, which can be combined with anti-CD20 antibodies or adoptive cellular therapies to treat non-Hodgkin lymphoma and mitigate resistance, which frequently depends on the CD20 antigen loss, offering new solutions to improve patient outcomes.<\/jats:p>","DOI":"10.3324\/haematol.2024.285826","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T02:56:47Z","timestamp":1734577007000},"page":"1555-1572","source":"Crossref","is-referenced-by-count":5,"title":["Potassium\/sodium cation carriers robustly upregulate CD20 antigen by targeting MYC, and synergize with anti- CD20 immunotherapies to eliminate malignant B cells"],"prefix":"10.3324","volume":"110","author":[{"given":"Anna","family":"Torun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Zdanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Miazek-Zapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jedrzejczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Ciechanowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Pilch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Skorzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miko\u0142aj","family":"S\u0142abicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Rymkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Barankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Martines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Struga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Winiarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Golab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz Z.","family":"Ratajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Huczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinis P.","family":"Calado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitar G.","family":"Efremov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdessamad","family":"Zerrouqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Pyrzynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"76531","doi-asserted-by":"crossref","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506.","DOI":"10.3324\/haematol.2019.243543"},{"key":"76532","doi-asserted-by":"crossref","unstructured":"Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers (Basel). 2023; 15(4):1003.","DOI":"10.3390\/cancers15041003"},{"key":"76533","doi-asserted-by":"crossref","unstructured":"Lopedote P, Shadman M. Targeted treatment of relapsed or refractory follicular lymphoma: focus on the therapeutic potential of mosunetuzumab. Cancer Manag Res. 2023; 15:257-264.","DOI":"10.2147\/CMAR.S381493"},{"key":"76534","doi-asserted-by":"crossref","unstructured":"Luo C, Wu G, Huang X. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):3255.","DOI":"10.1038\/s41598-021-82841-w"},{"key":"76535","doi-asserted-by":"crossref","unstructured":"Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018; 14(12):2820-2841.","DOI":"10.1080\/21645515.2018.1508624"},{"key":"76536","doi-asserted-by":"crossref","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab - the World\u2019s first oncology monoclonal antibody therapy. Front Oncol. 2018; 8:163.","DOI":"10.3389\/fonc.2018.00163"},{"key":"76537","doi-asserted-by":"crossref","unstructured":"Tomita A. Genetic and epigenetic modulation of CD20 expression in B-cell malignancies: molecular mechanisms and significance to rituximab resistance. J Clin Exp Hematop. 2016; 56(2):89-99.","DOI":"10.3960\/jslrt.56.89"},{"key":"76538","doi-asserted-by":"crossref","unstructured":"Ang Z, Paruzzo L, Hayer KE. Alternative splicing of its 5\u2019-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood. 2023; 142(20):1724-1739.","DOI":"10.1182\/blood.2023020400"},{"key":"76539","doi-asserted-by":"crossref","unstructured":"Prevodnik VK, Lavrencak J, Horvat M, Novakovic BJ. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011; 6:33.","DOI":"10.1186\/1746-1596-6-33"},{"key":"76540","doi-asserted-by":"crossref","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023; 329(11):918-932.","DOI":"10.1001\/jama.2023.1946"},{"key":"76541","doi-asserted-by":"crossref","unstructured":"Burger JA, Sivina M, Jain N. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019; 133(10):1011-1019.","DOI":"10.1182\/blood-2018-10-879429"},{"key":"76542","doi-asserted-by":"crossref","unstructured":"Bojarczuk K, Siernicka M, Dwojak M. B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia. 2014; 28(5):1163-1167.","DOI":"10.1038\/leu.2014.12"},{"key":"76543","doi-asserted-by":"crossref","unstructured":"Pyrzynska B, Dwojak M, Zerrouqi A. FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology. 2018; 7(5):e1423183.","DOI":"10.1080\/2162402X.2017.1423183"},{"key":"76544","doi-asserted-by":"crossref","unstructured":"Kim JH, Choi AR, Kim YK, Kim HS, Yoon S. Low amount of salinomycin greatly increases Akt activation, but reduces activated p70S6K levels. Int J Mol Sci. 2013; 14(9):17304-17318.","DOI":"10.3390\/ijms140917304"},{"key":"76545","doi-asserted-by":"crossref","unstructured":"Gupta PB, Onder TT, Jiang G. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659.","DOI":"10.1016\/j.cell.2009.06.034"},{"key":"76546","doi-asserted-by":"crossref","unstructured":"Qi D, Liu Y, Li J, Huang JH, Hu X, Wu E. Salinomycin as a potent anticancer stem cell agent: State of the art and future directions. Med Res Rev. 2022; 42(3):1037-1063.","DOI":"10.1002\/med.21870"},{"key":"76547","doi-asserted-by":"crossref","unstructured":"Mai TT, Hamai A, Hienzsch A. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. 2017; 9(10):1025-1033.","DOI":"10.1038\/nchem.2778"},{"key":"76548","doi-asserted-by":"crossref","unstructured":"Arfaoui A, Rioualen C, Azzoni V. A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Mol Med. 2019; 11(10):e9930.","DOI":"10.15252\/emmm.201809930"},{"key":"76549","doi-asserted-by":"crossref","unstructured":"Wang H, Zhang H, Zhu Y, Wu Z, Cui C, Cai F. Anticancer mechanisms of salinomycin in breast cancer and its clinical applications. Front Oncol. 2021; 11:654428.","DOI":"10.3389\/fonc.2021.654428"},{"key":"76550","doi-asserted-by":"crossref","unstructured":"Antoszczak M, Huczynski A. Salinomycin and its derivatives - a new class of multiple-targeted \u201cmagic bullets\u201d. Eur J Med Chem. 2019; 176:208-227.","DOI":"10.1016\/j.ejmech.2019.05.031"},{"key":"76551","doi-asserted-by":"crossref","unstructured":"Tefas LR, Barbalata C, Tefas C, Tomuta I. Salinomycin-based drug delivery systems: overcoming the hurdles in cancer therapy. Pharmaceutics. 2021; 13(8):1120.","DOI":"10.3390\/pharmaceutics13081120"},{"key":"76552","doi-asserted-by":"crossref","unstructured":"Ekinci IB, Chlodowska A, Olejnik M. Ionophore toxicity in animals: a review of clinical and molecular aspects. Int J Mol Sci. 2023; 24(2):1696.","DOI":"10.3390\/ijms24021696"},{"key":"76553","doi-asserted-by":"crossref","unstructured":"Bologna L, Gotti E, Da Roit F. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol. 2013; 190(1):231-239.","DOI":"10.4049\/jimmunol.1202645"},{"key":"76554","doi-asserted-by":"crossref","unstructured":"Dwojak M, Bobrowicz M, Bil J. Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. Blood Cancer J. 2015; 5(4):e300.","DOI":"10.1038\/bcj.2015.27"},{"key":"76555","doi-asserted-by":"crossref","unstructured":"Tremblay-McLean A, Coenraads S, Kiani Z, Dupuy FP, Bernard NF. Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function. BMC Immunol. 2019; 20(1):8.","DOI":"10.1186\/s12865-018-0272-x"},{"key":"76556","doi-asserted-by":"crossref","unstructured":"Sang Y, Kong P, Zhang S. SGK1 in human cancer: emerging roles and mechanisms. Front Oncol. 2020; 10:608722.","DOI":"10.3389\/fonc.2020.608722"},{"key":"76557","doi-asserted-by":"crossref","unstructured":"Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem. 1999; 274(24):16741-16746.","DOI":"10.1074\/jbc.274.24.16741"},{"key":"76558","doi-asserted-by":"crossref","unstructured":"Di Pietro N, Panel V, Hayes S. Serum- and glucocorticoid-inducible kinase 1 (SGK1) regulates adipocyte differentiation via forkhead box O1. Mol Endocrinol. 2010; 24(2):370-380.","DOI":"10.1210\/me.2009-0265"},{"key":"76559","doi-asserted-by":"crossref","unstructured":"Brunet A, Bonni A, Zigmond MJ. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96(6):857-868.","DOI":"10.1016\/S0092-8674(00)80595-4"},{"key":"76560","doi-asserted-by":"crossref","unstructured":"Zhang X, Gan L, Pan H. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear\/cytoplasmic shuttling and DNA binding. J Biol Chem. 2002; 277(47):45276-45284.","DOI":"10.1074\/jbc.M208063200"},{"key":"76561","doi-asserted-by":"crossref","unstructured":"Seitz V, Butzhammer P, Hirsch B. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS One. 2011; 6(11):e26837.","DOI":"10.1371\/journal.pone.0026837"},{"key":"76562","doi-asserted-by":"crossref","unstructured":"Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt\u2019s lymphoma cells. Proc Natl Acad Sci U S A. 2003; 100(14):8164-8169.","DOI":"10.1073\/pnas.1332764100"},{"key":"76563","doi-asserted-by":"crossref","unstructured":"Pajic A, Spitkovsky D, Christoph B. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000; 87(6):787-793.","DOI":"10.1002\/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6"},{"key":"76564","doi-asserted-by":"crossref","unstructured":"Lee LYW, Woolley C, Starkey T. Serum- and glucocorticoid-induced kinase Sgk1 directly promotes the differentiation of colorectal cancer cells and restrains metastasis. Clin Cancer Res. 2019; 25(2):629-640.","DOI":"10.1158\/1078-0432.CCR-18-1033"},{"key":"76565","doi-asserted-by":"crossref","unstructured":"Bobrowicz M, Dwojak M, Pyrzynska B. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood. 2017; 130(14):1628-1638.","DOI":"10.1182\/blood-2016-08-736066"},{"key":"76566","doi-asserted-by":"crossref","unstructured":"Szydlowski M, Garbicz F, Jablonska E. Inhibition of PIM kinases in DLBCL targets MYC transcriptional program and augments the efficacy of anti-CD20 antibodies. Cancer Res. 2021; 81(23):6029-6043.","DOI":"10.1158\/0008-5472.CAN-21-1023"},{"key":"76567","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Schumich A, Printz D. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008; 112(10):3982-3988.","DOI":"10.1182\/blood-2008-06-164129"},{"key":"76568","doi-asserted-by":"crossref","unstructured":"Vanneste M, Huang Q, Li M. High content screening identifies monensin as an EMT-selective cytotoxic compound. Sci Rep. 2019; 9(1):1200.","DOI":"10.1038\/s41598-018-38019-y"},{"key":"76569","doi-asserted-by":"crossref","unstructured":"Wang X, Wu X, Zhang Z. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep. 2018; 8(1):17914.","DOI":"10.1038\/s41598-018-36214-5"},{"key":"76570","doi-asserted-by":"crossref","unstructured":"Roulston GD, Burt CL, Kettyle LM. Low-dose salinomycin induces anti-leukemic responses in AML and MLL. Oncotarget. 2016; 7(45):73448-73461.","DOI":"10.18632\/oncotarget.11866"},{"key":"76571","doi-asserted-by":"crossref","unstructured":"Urbaniak A, Delgado M, Antoszczak M, Huczynski A, Chambers TC. Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro. Biomed Pharmacother. 2018; 99:384-390.","DOI":"10.1016\/j.biopha.2018.01.081"},{"key":"76572","doi-asserted-by":"crossref","unstructured":"Yusenko MV, Trentmann A, Andersson MK. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. Cancer Lett. 2020; 479:61-70.","DOI":"10.1016\/j.canlet.2020.01.039"},{"key":"76573","doi-asserted-by":"crossref","unstructured":"Yu D, Dews M, Park A, Tobias JW, Thomas-Tikhonenko A. Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res. 2005; 65(12):5454-5461.","DOI":"10.1158\/0008-5472.CAN-04-4197"},{"key":"76574","doi-asserted-by":"crossref","unstructured":"Antoszczak M. A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents. Eur J Med Chem. 2019; 166:48-64.","DOI":"10.1016\/j.ejmech.2019.01.034"},{"key":"76575","doi-asserted-by":"crossref","unstructured":"Antonenko YN, Rokitskaya TI, Huczynski A. Electrogenic and nonelectrogenic ion fluxes across lipid and mitochondrial membranes mediated by monensin and monensin ethyl ester. Biochim Biophys Acta. 2015; 1848(4):995-1004.","DOI":"10.1016\/j.bbamem.2015.01.005"},{"key":"76576","unstructured":"Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012; 2(6):676-690."},{"key":"76577","doi-asserted-by":"crossref","unstructured":"van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res. 2006; 12(13):4027-4035.","DOI":"10.1158\/1078-0432.CCR-06-0066"},{"key":"76578","doi-asserted-by":"crossref","unstructured":"Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181.","DOI":"10.1080\/14712598.2020.1822318"},{"key":"76579","doi-asserted-by":"crossref","unstructured":"Terui Y, Sakurai T, Mishima Y. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci. 2006; 97(1):72-79.","DOI":"10.1111\/j.1349-7006.2006.00139.x"},{"key":"76580","doi-asserted-by":"crossref","unstructured":"Hu W, Ge X, You T. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res. 2011; 71(6):2298-2307.","DOI":"10.1158\/0008-5472.CAN-10-3016"},{"key":"76581","doi-asserted-by":"crossref","unstructured":"God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol. 2010; 2010:516047.","DOI":"10.1155\/2010\/516047"},{"key":"76582","doi-asserted-by":"crossref","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017; 8:1124.","DOI":"10.3389\/fimmu.2017.01124"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11877\/78518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11877\/78519","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11877\/77919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:53Z","timestamp":1794046073000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285826","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}